Navigation Links
Dual gene therapy suppresses lung cancer in preclinical test

Combination gene therapy delivered in lipid-based nanoparticles drastically reduces the number and size of human non-small cell lung cancer tumors in mice, researchers at The University of Texas M. D. Anderson Cancer Center and the University of Texas Southwestern Medical Center report in the Jan. 15 edition of Cancer Research.

Two tumor-suppressing genes given intravenously reduced cancer separately but had their most powerful effect when administered together, cutting the number of tumors per mouse by 75 percent and the weight of tumors by 80 percent.

"In cancer treatment we have combination chemotherapy, and we also combine different modes of therapy - surgery, radiation and chemotherapy. Now you've got the possibility of combined targeted gene therapy," said Jack Roth, M.D., professor and chair of the M. D. Anderson Department of Thoracic and Cardiovascular Surgery and a senior researcher on the project.

The genes wrapped in the nanoparticles were p53, a well-known tumor suppressor that works by causing defective cells to commit suicide and is often shut down or defective in cancer cells, and FUS1, a tumor-suppressor discovered by the research group that is deficient in most human lung cancers. Each nanoparticle carried one of the two genes.

The Cancer Research paper reports that FUS1 works with p53 to force the lung cancer cells to kill themselves - a process known as apoptosis.

Further analysis showed that the combination achieved greater cell suicide because FUS1 suppresses a gene that expresses a protein known to rapidly degrade p53, says senior author Lin Ji, Ph.D., M. D. Anderson associate professor of thoracic and cardiovascular surgery.

The FUS1/p53 combination also activates a cell suicide pathway based in the cells' mitochondria, their energy powerhouse.

Lab experiments first showed that the gene combination cut the number of viable cells in four lines of human non-small cell lung ca
'"/>

Source:University of Texas M. D. Anderson Cancer Center


Page: 1 2

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Columbia research lifts major hurdle to gene therapy for cancer
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Gene therapy converts dead bone graft to new, living tissue
5. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
8. New therapy for HIV/AIDS eliminates needles and excessive toxicity
9. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
10. Gene therapy for Parkinsons disease moves forward in animals
11. Pulsating ultrasound enhances gene therapy for tumors
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Dual gene therapy suppresses lung cancer preclinical test

(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
(Date:6/24/2015)... Biometry authentication provider KeyLemon today announced ... one face in. Logo - ... in, entering the expanding biometric authentication market in ... answer to the password problem. With advanced face ... KeyLemon, one face in allows users to securely ...
(Date:6/18/2015)... , June 18, 2015 This report ... Million by the following Product Segments, which includes Immunoassay ... Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and Nephelometric Immunoassay ... US, Canada , Japan ... Asia-Pacific , Latin America , ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29
... Madison, WI, February 24, 2009 | Tiny sediment grains ... minerals in an open fabric that results in a ... grains. Scientists at the U.S. Geological Survey (USGS) are ... composition of these coatings on sediment grains in the ...
... with the tiny fruit fly and then moving into mice and ... of the same gene suppresses cancer in all three organisms. Reciprocally, ... in mammals leads to cancer. The authors show there is ... with a drug. They report their findings in two papers in ...
... today (Monday) to advise the country on how it ... The biotechonology experts from the Belfast-based University are ... cost the world economy around $200 billion in lost ... year. A delegation led by Dr Gerry Brennan ...
Cached Biology News:Ultra-fine coatings on sediment grains influence nitrate and sulfate storage in soil 2Suppressing cancer with a master control gene 2Reduction in parasite infections ahead for India 2
(Date:6/29/2015)... 2015   For the seventh year running, Across Health ... overall digital maturity called the Multichannel Maturometer . ... not maturing fast enough. While it,s true that technology ... overall and customers are increasingly "digital natives", pharma still ... engagement.  ...
(Date:6/26/2015)... , June 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" ... announced that all nominees listed in the management ... at its 2015 Annual Meeting of Shareholders, held ... by ballot, the following 5 nominees proposed by ... to serve until the Company,s next Annual Meeting ...
(Date:6/26/2015)... (PRWEB) , ... June 26, 2015 , ... ... today announced that its SimplePrep™ technologies have been integrated into a sample prep ... Space Station (ISS) as a part of the NASA’s WetLab-2 Project. , On ...
(Date:6/26/2015)... ... ... ReliantHeart, Inc. , an innovative supplier of advanced mechanical circulatory assist technologies ... (HA5) to the 68th consecutive implant, there has been no evidence of de novo ... referred to as de novo thrombus. De novo thrombus can hide under the impeller ...
Breaking Biology Technology:Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 2iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 3Claremont BioSolutions’ SimplePrep™ Products Deployed in NASA Wetlab-2 Project Slated for June 28th Flight to International Space Station aboard SpaceX CRS-7 2Claremont BioSolutions’ SimplePrep™ Products Deployed in NASA Wetlab-2 Project Slated for June 28th Flight to International Space Station aboard SpaceX CRS-7 3HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 2HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 3
... Calif., July 27, 2011 Sangamo BioSciences, Inc. (Nasdaq: ... and accomplishments. For the second quarter ended ... $10.3 million, or $0.20 per share, compared to a net ... same period in 2010. As of June 30, 2011, the ...
... Corporation , a leading global provider of microwave laboratory ... microwave peptide synthesis products . In FY2011 year-to-date, the ... in its automated peptide synthesizer instrument sales and is ... systems. Additionally, CEM,s products were well received at the ...
... 2011 Linden LLC, a Chicago-based healthcare private ... an investment in Strata Pathology Services, Inc., a ... Headquartered in Lexington, Massachusetts, Strata offers ... oral pathology, gastroenterology and gynecology segments. Since 1984, ...
Cached Biology Technology:Sangamo BioSciences Reports Second Quarter 2011 Financial Results 2Sangamo BioSciences Reports Second Quarter 2011 Financial Results 3Sangamo BioSciences Reports Second Quarter 2011 Financial Results 4Sangamo BioSciences Reports Second Quarter 2011 Financial Results 5Sangamo BioSciences Reports Second Quarter 2011 Financial Results 6Sangamo BioSciences Reports Second Quarter 2011 Financial Results 7Record Year for CEM's Peptide Synthesis Business 2Record Year for CEM's Peptide Synthesis Business 3Linden Enters Anatomic Pathology Sector Through Investment in Strata Pathology Services, Inc. 2